1
|
Tolaney S, Chan A, Petrakova K, Delaloge S, Campone M, Iwata H, Peddi P, Kaufman P, de Kermadec E, Liu Q, Cohen P, Paux G, Im SA. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
2
|
Yardley D, Yap Y, Azim H, De Boer R, Campone M, Ring A, De Laurentiis M, O'Shaughnessy J, Cortés J, Chattar Y, Thuerigen A, Zarate J, Nusch A. 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Jouannaud C, Emile G, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, Martin AL, Everhard S, Di Meglio A. Factors associated with enrolment in clinical trials among women with early-stage breast cancer. ESMO Open 2022; 7:100513. [PMID: 35724624 PMCID: PMC9271499 DOI: 10.1016/j.esmoop.2022.100513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 05/16/2022] [Accepted: 05/17/2022] [Indexed: 11/26/2022] Open
Abstract
Background Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer. Methods We included 9516 patients with stage I-III breast cancer from the multicenter, prospective CANTO study (NCT01993498), followed-up until year 4 (Y4) post-diagnosis. We assessed factors associated with enrolment using multivariable logistic regression. In exploratory, propensity score matched analyses, we used multiple linear regression to evaluate the relationship of enrolment in clinical trials with the European Organisation for Research and Treatment of Cancer Quality Of Life (QoL) questionnaire (EORTC QLQ-C30) Summary Score and described clinical outcomes (distant disease event, invasive disease event, and death by any cause) according to enrolment. Results Overall, 1716 patients (18%) were enrolled in a clinical trial until Y4 post-diagnosis of breast cancer. Socioeconomic factors were not associated with enrolment. Centres of intermediate volume were most likely to enrol patients in clinical trials [versus low volume, odds ratio 1.45 (95% confidence interval (CI) 1.08-1.95), P = 0.0124]. Among 2118 propensity score matched patients, enrolment was associated with better QoL at Y4 (adjusted mean difference versus not enrolled 1.37, 95% CI 0.03-2.71, P = 0.0458), and clinical outcomes (enrolled versus not enrolled, distant disease event 7.3% versus 10.1%, P = 0.0206; invasive disease event 8.2% versus 10.5%, P = 0.0732; death by any cause 2.8% versus 3.7%, P = 0.2707). Conclusions In this large study, one in five patients enrolled on a clinical trial until Y4 after diagnosis of early breast cancer. Geographical and centre-related factors were significantly associated with enrolment in clinical trials. Inclusion in clinical trials seemed associated with improved QoL and clinical outcomes. Access to innovation for early-stage breast cancer patients should be encouraged and facilitated by overcoming organizational and geographical barriers to recruitment. The proportion of patients who access innovation through participation in clinical trials is generally limited. Rate of enrolment in clinical trials among women with early breast cancer exceeded what previously found in other settings. Clinical and geographical factors were associated to access to innovation in clinical trials. Enrolment in clinical trials is associated with better quality of life and clinical outcomes.
Collapse
Affiliation(s)
- D Presti
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - J Havas
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - D Soldato
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy
| | - P Lapidari
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
| | - E Martin
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - B Pistilli
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | | | - G Emile
- Centre François Baclesse, Caen, France
| | - O Rigal
- Centre Henri Becquerel, Rouen, France
| | | | - P Soulie
- Institut de Cancérologie de L'ouest -Paul Papin, Angers, France
| | | | - C Tarpin
- Institut Paoli Calmettes, Marseille, France
| | - M Campone
- Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France
| | | | | | | | - A Di Meglio
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.
| |
Collapse
|
4
|
Rugo H, Drumea K, Lee S, Campone M, Van Poznak C, Neven P, Vega Alonso E, Naume B, Siegel J, Li R, Uema D, Wagner V, Coleman R. 182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston S, Reinisch M, Tolaney SM. Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study. Ann Oncol 2022; 33:616-627. [PMID: 35337972 DOI: 10.1016/j.annonc.2022.03.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/07/2022] [Accepted: 03/11/2022] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high risk, early breast cancer demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PRO) are presented. PATIENTS AND METHODS The safety population included all patients who received at least one dose of study treatment (n=5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality-of-life, ET symptoms, fatigue, and side effect burden were assessed. RESULTS The addition of abemaciclib to ET resulted in higher incidence of Grade≥3 AEs (49.7% vs 16.3% with ET alone), predominantly laboratory cytopenias (e.g., neutropenia [19.6%]) without clinical complications. Abemaciclib-treated patients experienced more serious adverse events (SAEs; 13.3% vs 7.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to Grade1/2 AEs (66.8%). AEs were managed with comedications (e.g., antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (Grade1/2: 77%); Grade2/3 events were highest in the first month (20.5%), most short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTE) were higher with abemaciclib+ET (2.5%) vs ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen vs AIs (4.3% vs 1.8%). PROs were similar between arms, including being 'bothered by side effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported "a little bit" or "somewhat". CONCLUSION In patients with high risk EBC, adjuvant abemaciclib+ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
Collapse
Affiliation(s)
- H S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas TX, USA
| | - F Boyle
- Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney; University of Sydney, Sydney, Australia
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan
| | - R Broom
- Auckland City Hospital, Auckland, New Zealand
| | - I Blancas
- Hospital Universitario Clínico San Cecilio, Granada, Spain; Medicine Department. University of Granada, Spain
| | - M Gumus
- Istanbul Medeniyet University, School of Medicine, Istanbul, Turkey
| | | | - Y-H Im
- Division of Hematology/Medical Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - F Zagouri
- National and Kapodistrian University of Athens, Department of Clinical Therapeutics, School of Medicine, Athens, Greece
| | - C Song
- Fujian Medical University Union Hospital, Fujian, China
| | - M Campone
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes / Saint-Herblain, France
| | | | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | - M Hulstijn
- Eli Lilly and Company, Indianapolis, USA
| | - J Brown
- Eli Lilly and Company, Indianapolis, USA
| | | | - Ran Wei
- Eli Lilly and Company, Indianapolis, USA
| | - S Johnston
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Reinisch
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | | | | |
Collapse
|
6
|
Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Martin AL, Everhard S, Jouannaud C, Levy C, Rigal O, Fournier M, Soulié P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, André F, Vaz-Luis I, Di Meglio A. 134P Enrolment in clinical trials (CT) among patients (pts) with early breast cancer (BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Autier L, Augereau P, Lebrec N, Seegers V, Soulié P, Patsouris A, Campone M, Dupoiron D. 322P Intrathecal catheter for chemotherapy in leptomeningeal metastatic breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Domergue C, Martin E, Lemarié C, Jézéquel P, Frenel JS, Augereau P, Campone M, Patsouris A. 156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol 2021; 32:1245-1255. [PMID: 34224826 DOI: 10.1016/j.annonc.2021.06.024] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 06/15/2021] [Accepted: 06/27/2021] [Indexed: 10/21/2022] Open
Abstract
BACKGROUND The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. PATIENTS AND METHODS Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. RESULTS Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). CONCLUSIONS Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design.
Collapse
Affiliation(s)
- D Miles
- Mount Vernon Cancer Centre, Northwood, UK.
| | - E Ciruelos
- Medical Oncology Department Breast Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; HM Hospitales, Madrid, Spain
| | - A Schneeweiss
- Gynecologic Oncology Division, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - F Puglisi
- Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Centro di Riferimento Oncologico Aviano-National Cancer Institute, Aviano, Italy; Department of Medicine, University of Udine, Udine, Italy
| | - T Peretz-Yablonski
- Sharett Institute of Oncology and Center for Malignant Breast Diseases, Hadassah Medical Organization, Jerusalem, Israel
| | - M Campone
- Institut de Cancérologie de l'Ouest, Angers, France
| | - I Bondarenko
- Oncology and Medical Radiology Department, City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine
| | - Z Nowecki
- Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland
| | - H Errihani
- National Institute of Oncology, Mohammed V Rabat University, Rabat, Morocco
| | - S Paluch-Shimon
- Division of Oncology, Sheba Medical Centre, Tel Hashomer, Israel
| | - A Wardley
- National Institute for Health Research Manchester Clinical Research Facility at the Christie NHS Foundation Trust, Manchester, UK; Outreach Research & Innovation Group, Manchester, UK
| | | | - P Trask
- Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, USA
| | - Y du Toit
- Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - C Pena-Murillo
- Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - V Revelant
- Global Product Development, Portfolio Clinical Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - D Klingbiel
- Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - T Bachelot
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | | |
Collapse
|
10
|
Bachelot T, Dalenc F, Chabaud S, Cottu P, Allouache D, Brain E, Jacquin JP, Grenier J, Venat Bouvet L, Brunt M, Campone M, Del Piano F, Debled M, Hardy Bessard AC, Giacchetti S, Bliss J, Canon JL, Lemonnier J, Cameron D, André F. Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Blay JY, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D, Barranger E, Campone M, Conroy T, Coutant C, De Crevoisier R, Debreuve-Theresette A, Delord JP, Fumoleau P, Gentil J, Gomez F, Guerin O, Jaffré A, Lartigau E, Lemoine C, Mahe MA, Mahon FX, Mathieu-Daude H, Merrouche Y, Penault-Llorca F, Pivot X, Soria JC, Thomas G, Vera P, Vermeulin T, Viens P, Ychou M, Beaupere S. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. ESMO Open 2021; 6:100134. [PMID: 33984676 PMCID: PMC8134718 DOI: 10.1016/j.esmoop.2021.100134] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/01/2021] [Accepted: 04/02/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer comprehensive cancer centers in France. PATIENTS AND METHODS The number of patients diagnosed and treated within 17 of the 18 Unicancer centers was collected in 2020 and compared with that during the same periods between 2016 and 2019. Unicancer centers treat close to 20% of cancer patients in France yearly. The reduction in the number of patients attending the Unicancer centers was analyzed per regions and cancer types. The impact of delayed care on cancer-related deaths was calculated based on different hypotheses. RESULTS A 6.8% decrease in patients managed within Unicancer in the first 7 months of 2020 versus 2019 was observed. This reduction reached 21% during April and May, and was not compensated in June and July, nor later until November 2020. This reduction was observed only for newly diagnosed patients, while the clinical activity for previously diagnosed patients increased by 4% similar to previous years. The reduction was more pronounced in women, in breast and prostate cancers, and for patients without metastasis. Using an estimated hazard ratio of 1.06 per month of delay in diagnosis and treatment of new patients, we calculated that the delays observed in the 5-month period from March to July 2020 may result in an excess mortality due to cancer of 1000-6000 patients in coming years. CONCLUSIONS In this study, the delays in cancer patient management were observed only for newly diagnosed patients, more frequently in women, for breast cancer, prostate cancer, and nonmetastatic cancers. These delays may result is an excess risk of cancer-related deaths in the coming years.
Collapse
Affiliation(s)
- J Y Blay
- Centre Leon Berard, Lyon, France.
| | | | | | - C Cropet
- Centre Leon Berard, Lyon, France
| | | | - D Perol
- Centre Leon Berard, Lyon, France
| | | | - M Campone
- Institut de Cancerologie de l'Ouest, Nantes et Angers, France
| | - T Conroy
- Institut de Cancerologie de Lorraine, Nancy, France
| | - C Coutant
- Centre George Francoise Leclerc, Dijon, France
| | | | | | - J P Delord
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | | | - J Gentil
- Centre George Francoise Leclerc, Dijon, France
| | - F Gomez
- Centre Leon Berard, Lyon, France
| | - O Guerin
- Institut de Cancerologie de l'Ouest, Nantes et Angers, France
| | | | | | - C Lemoine
- Institut Paoli-Calmettes, Marseille, France
| | - M A Mahe
- Centre François Baclesse, Caen, France
| | | | - H Mathieu-Daude
- Institut de Cancerologie de Montpellier, Montpellier, France
| | | | | | - X Pivot
- Centre Paul Strauss/ICANS, Strasbourg, France
| | | | - G Thomas
- Centre François Baclesse, Caen, France
| | - P Vera
- Centre Henri Becquerel, Rouen, France
| | | | - P Viens
- Institut Paoli-Calmettes, Marseille, France
| | - M Ychou
- Institut de Cancerologie de Montpellier, Montpellier, France
| | | |
Collapse
|
12
|
Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, Mouret-Reynier MA, Gonçalves A, Dalenc F, Verret B, Campone M, Ferrero JM, Levy C, Fumet JD, Lefeuvre-Plesse C, Petit T, Jouannaud C, Larrouquere L, Chevrot M, Cabel L. 102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
13
|
Toi M, Harbeck N, Puig J, Cruz J, Seo J, Takahashi M, Hulstijn M, Twum E, Regev A, San Antonio B, Median D, Campone M. 44O Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Bertaut A, Blanc J, Pistilli B, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu P, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Martin AL, Jacquet Jacquet A, Briot N, Vaz-Luis I. 151P Impact of germline BRCA (gBRCA) mutation (m) status on clinical characteristics and patterns of care among women with early breast cancer (eBC): An analysis of the observational prospective CANTO cohort. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2020; 32:208-217. [PMID: 33246021 DOI: 10.1016/j.annonc.2020.11.011] [Citation(s) in RCA: 230] [Impact Index Per Article: 57.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/11/2020] [Accepted: 11/13/2020] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with poor prognosis. The SOLAR-1 trial showed that the addition of alpelisib to fulvestrant treatment provided statistically significant and clinically meaningful progression-free survival (PFS) benefit in PIK3CA-mutated, HR+, HER2- ABC. PATIENTS AND METHODS Men and postmenopausal women with HR+, HER2- ABC whose disease progressed on or after aromatase inhibitor (AI) were randomized 1 : 1 to receive alpelisib (300 mg/day) plus fulvestrant (500 mg every 28 days and once on day 15) or placebo plus fulvestrant. Overall survival (OS) in the PIK3CA-mutant cohort was evaluated by Kaplan-Meier methodology and a one-sided stratified log-rank test was carried out with an O'Brien-Fleming efficacy boundary of P ≤ 0.0161. RESULTS In the PIK3CA-mutated cohort (n = 341), median OS [95% confidence interval (CI)] was 39.3 months (34.1-44.9) for alpelisib-fulvestrant and 31.4 months (26.8-41.3) for placebo-fulvestrant [hazard ratio (HR) = 0.86 (95% CI, 0.64-1.15; P = 0.15)]. OS results did not cross the prespecified efficacy boundary. Median OS (95% CI) in patients with lung and/or liver metastases was 37.2 months (28.7-43.6) and 22.8 months (19.0-26.8) in the alpelisib-fulvestrant and placebo-fulvestrant arms, respectively [HR = 0.68 (0.46-1.00)]. Median times to chemotherapy (95% CI) for the alpelisib-fulvestrant and placebo-fulvestrant arms were 23.3 months (15.2-28.4) and 14.8 months (10.5-22.6), respectively [HR = 0.72 (0.54-0.95)]. No new safety signals were observed with longer follow-up. CONCLUSIONS Although the analysis did not cross the prespecified boundary for statistical significance, there was a 7.9-month numeric improvement in median OS when alpelisib was added to fulvestrant treatment of patients with PIK3CA-mutated, HR+, HER2- ABC. Overall, these results further support the statistically significant prolongation of PFS observed with alpelisib plus fulvestrant in this population, which has a poor prognosis due to a PIK3CA mutation. CLINICALTRIALS. GOV ID NCT02437318.
Collapse
Affiliation(s)
- F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif and Paris Saclay University, Orsay, France.
| | - E M Ciruelos
- Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - D Juric
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA
| | - S Loibl
- Department of Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany
| | - M Campone
- Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, Nantes Cedex, France
| | - I A Mayer
- Hematology/Oncology, Vanderbilt University, Nashville, USA
| | - G Rubovszky
- Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
| | - T Yamashita
- Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
| | - B Kaufman
- Medical Oncology, Tel Aviv University, Sheba Medical Centre, Tel Hashomer, Israel
| | - Y-S Lu
- Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan
| | - K Inoue
- Breast Surgery, Saitama Cancer Center, Saitama, Japan
| | - Z Pápai
- Medical Oncology, Hungarian Defence Forces Medical Centre, Budapest, Hungary
| | - M Takahashi
- Breast Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan
| | - F Ghaznawi
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - D Mills
- Novartis Pharma AG, Basel, Switzerland
| | - M Kaper
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - M Miller
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - P F Conte
- Medical Oncology, Universita di Padova and Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - H Iwata
- Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan
| | - H S Rugo
- Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| |
Collapse
|
16
|
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, Campone M, Hamilton E, Sohn J, Guarneri V, Cortes J, Neven P, Boyle F, Smith I, Frenzel M, Headley D, Wei R, Cox J, O'Shaughnessy J, Rastogi P. 2MO Abemaciclib in high risk early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, Campone M, Hamilton E, Sohn J, Guarneri V, Cortés J, Neven P, Boyle F, Smith I, Headley D, Wei R, Frenzel M, Cox J, O'Shaughnessy J, Rastogi P. LBA5_PR Abemaciclib in high risk early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2238] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
André F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer I, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Papai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte P, Iwata H, Rugo H. LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2246] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
19
|
Frenel JS, Cartron PF, Gourmelon C, Campion L, Aumont M, Augereau P, Ducray F, Loussouarn D, Lallier L, Robert M, Campone M. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
20
|
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot J, du Toit Y, Klingbiel D, Revelant V, Bachelot T. 288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
21
|
Chandarlapaty S, Bardia A, Lord S, Linden H, Pelekanou V, Ternes N, Ming J, Boutet V, Boitier E, Gosselin A, Lee JS, Dos-Santos Bele W, Protopopov A, Celanovic M, Bauchet AL, Campone M. 277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.379] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
22
|
Cottu P, Ring A, Marchetti P, Cardoso F, Salvador J, Neven P, Papazisis K, Campone M, Bachelot T, Menon-Singh L, Wu J, Zhou K, De Laurentiis M. 333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
23
|
Jerusalem G, Onesti C, Generali D, Harbeck N, Wildiers H, Curigliano G, Campone M, Tjan-Heijnen V, Martin M, Cristofanilli M, Pusztai L, Bartsch R, Peeters M, Berchem G, Tagliamento M, Cortés J, Ruhstaller T, Ciruelos E, Rottey S, Rugo H. LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology. Ann Oncol 2020. [PMCID: PMC7506324 DOI: 10.1016/j.annonc.2020.08.2317] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
24
|
Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020; 31:1001-1010. [PMID: 32416251 DOI: 10.1016/j.annonc.2020.05.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 04/30/2020] [Accepted: 05/04/2020] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is approved in multiple countries for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer following progression on or after endocrine therapy. A detailed understanding of alpelisib's safety profile should inform adverse event (AE) management and enhance patient care. PATIENTS AND METHODS AEs in the phase III SOLAR-1 trial were assessed in patients with and without PIK3CA mutations. The impact of protocol-specified AE-management recommendations was evaluated, including an amendment to optimize hyperglycemia and rash management. RESULTS Patients were randomly assigned to receive fulvestrant plus alpelisib (n = 284) or placebo (n = 287). The most common grade 3/4 AEs with alpelisib were hyperglycemia (grade 3, 32.7%; grade 4, 3.9%), rash (grade 3, 9.9%), and diarrhea (grade 3, 6.7%). Median time to onset of grade ≥3 toxicity was 15 days (hyperglycemia, based on fasting plasma glucose), 13 days (rash), and 139 days (diarrhea). Metformin alone or in combination with other antidiabetic agents was used by most patients (87.1%) with hyperglycemia. Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% versus 64.1%) and severity of rash (grade 3, 11.6% versus 22.7%) versus no preventative medication. Discontinuations due to grade ≥3 AEs were lower following more-detailed AE management guidelines (7.9% versus 18.1% previously). Patients with PIK3CA mutations had a median alpelisib dose intensity of 248 mg/day. Median progression-free survival with alpelisib was 12.5 and 9.6 months for alpelisib dose intensities of ≥248 mg/day and <248 mg/day, respectively, compared with 5.8 months with placebo. CONCLUSIONS Hyperglycemia and rash occurred early during alpelisib treatment, while diarrhea occurred at a later time point. Early identification, prevention, and intervention, including concomitant medications and alpelisib dose modifications, resulted in less severe toxicities. Reductions in treatment discontinuations and improved progression-free survival at higher alpelisib dose intensities support the need for optimal AE management. CLINICALTRIALS. GOV ID NCT02437318.
Collapse
Affiliation(s)
- H S Rugo
- Department of Medicine, Division of Hematology and Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
| | - F André
- Department of Medical Oncology, INSERM U981, Gustave Roussy, Université Paris-Sud, Villejuif, France
| | - T Yamashita
- Department of Breast and Endocrine Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan
| | - H Cerda
- Clinica RedSalud Vitacura, Santiago, Chile
| | | | - S M Stemmer
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel
| | - J C Jurado
- Hospital Universitario Canarias, S/C Tenerife, Islas Canarias, Spain
| | - D Juric
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA
| | - I Mayer
- Department of Medicine, Hematology and Oncology, Vanderbilt University, Nashville, USA
| | - E M Ciruelos
- Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - H Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - P Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padua and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy
| | - M Campone
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France
| | - C Wilke
- Novartis Pharma AG, Basel, Switzerland
| | - D Mills
- Novartis Pharma AG, Basel, Switzerland
| | - A Lteif
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - M Miller
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | | | - S Loibl
- Department of Medicine and Research, German Breast Group, Neu-Isenburg; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
| |
Collapse
|
25
|
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2020; 30:397-404. [PMID: 30475950 DOI: 10.1093/annonc/mdy517] [Citation(s) in RCA: 488] [Impact Index Per Article: 122.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival. RESULTS All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs. CONCLUSIONS Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02447003.
Collapse
Affiliation(s)
- S Adams
- Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA.
| | - P Schmid
- Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK
| | - H S Rugo
- Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - E P Winer
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - A Awada
- Oncology Medicine Departmen, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
| | - D W Cescon
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Campone
- Institut de Cancerologie de l'Ouest, Nantes, France
| | - R Nanda
- Department of Medicin, Section of Hematology/Oncology, The University of Chicago, Chicago, USA
| | - R Hui
- Westmead Hospital and the University of Sydney, Sydney, Australia
| | - G Curigliano
- Department of Oncology and Hematology, University of Milano, Milan; IEO, European Institute of Oncology IRCCS, Milano, Milan, Italy
| | - D Toppmeyer
- Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA
| | - J O'Shaughnessy
- Baylor University Medical Center, Dallas; Texas Oncology, Dallas; US Oncology, Dallas, USA
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S Paluch-Shimon
- Breast Cancer Service for Young Women, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - A R Tan
- Levine Cancer Institute, Atrium Health, Charlotte
| | - D Card
- Merck & Co., Inc., Kenilworth, USA
| | - J Zhao
- Merck & Co., Inc., Kenilworth, USA
| | | | - J Cortés
- Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona; Ramon y Cajal University Hospital, Madrid; IOB Institute of Oncology, Quiron Group, Barcelona, Spain
| |
Collapse
|
26
|
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 2020; 31:377-386. [PMID: 32067679 DOI: 10.1016/j.annonc.2019.11.006] [Citation(s) in RCA: 139] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 10/15/2019] [Accepted: 11/04/2019] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug family in the treatment landscape. PATIENTS AND METHODS A total of 649 patients with mBC from the SAFIR02 trial (NCT02299999), with available mutational profiles were selected for outcome analysis. PIK3CA mutations were prospectively determined by next-generation sequencing on metastatic samples. The mutational landscape of PIK3CA-mutated mBC was assessed by whole-exome sequencing (n = 617). Finally, the prognostic value of PIK3CA mutations during chemotherapy was assessed in plasma samples (n = 44) by next-generation sequencing and digital PCR. RESULTS Some 28% (104/364) of HR+/Her2- tumors and 10% (27/255) of triple-negative breast cancer (TNBC) presented a PIK3CA mutation (P < 0.001). PIK3CA-mutated HR+/Her2- mBC was less sensitive to chemotherapy [adjusted odds ratio: 0.40; 95% confidence interval (0.22-0.71); P = 0.002], and presented a worse overall survival (OS) compared with PIK3CA wild-type [adjusted hazard ratio: 1.44; 95% confidence interval (1.02-2.03); P = 0.04]. PIK3CA-mutated HR+/Her2- mBC was enriched in MAP3K1 mutations (15% versus 5%, P = 0.0005). In metastatic TNBC (mTNBC), the median OS in patients with PIK3CA mutation was 24 versus 14 months for PIK3CA wild-type (P = 0.03). We further looked at the distribution of PIK3CA mutation in mTNBC according to HR expression on the primary tumor. Some 6% (9/138) of patients without HR expression on the primary and 36% (14/39) of patients with HR+ on the primary presented PIK3CA mutation (P < 0.001). The level of residual PIK3CA mutations in plasma after one to three cycles of chemotherapy was associated with a poor OS [continuous variable, hazard ratio: 1.03, 95% confidence interval (1.01-1.05), P = 0.007]. CONCLUSION PIK3CA-mutated HR+/Her2- mBC patients present a poor outcome and resistance to chemotherapy. Patients with PIK3CA-mutated TNBC present a better OS. This could be explained by an enrichment of PIK3CA mutations in luminal BC which lost HR expression in the metastatic setting. TRIAL REGISTRATION SAFIR02 trial: NCT02299999.
Collapse
Affiliation(s)
- F Mosele
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - B Stefanovska
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France
| | - A Lusque
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - A Tran Dien
- Bioinformatics Platform, Gustave Roussy, Villejuif, France
| | - I Garberis
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; Paris-Saclay University, Paris, France
| | - N Droin
- Genomic Core Facility UMS AMMICA Gustave Roussy, Villejuif, France
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris, France; INSERM U900, Saint-Cloud, France; Paris-Saclay University, Paris, France
| | - M-P Sablin
- Department of Medical Oncology, Institut Curie, Paris, France
| | - L Lacroix
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France; Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - D Enrico
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - I Miran
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - C Jovelet
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - I Bièche
- Department of Genetics, Institut Curie, Paris, France; INSERM U1016, Paris Descartes University, Paris, France
| | - J-C Soria
- University of Paris-Sud, Orsay, France
| | - F Bertucci
- CRCM, Predictive Oncology team, Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Marseille, France
| | - H Bonnefoi
- Department of Medical Oncology, Institut Bergonie, Bordeaux, France
| | - M Campone
- Department of Medical Oncology, Institut of Cancerology Ouest, Nantes, France
| | - F Dalenc
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - T Bachelot
- Department of Medical Oncology, Center Leon Berard, Lyon, France
| | - A Jacquet
- Precision Medicine Group, UNICANCER, Paris, France
| | - M Jimenez
- Precision Medicine Group, UNICANCER, Paris, France
| | - F André
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; University of Paris-Sud, Orsay, France.
| |
Collapse
|
27
|
Le Méhauté R, Dagher E, Loussouarn D, Abadie J, Campone M, Nguyen F. PERITUMOURAL MUM1+ Plasma Cells are Associated With Poor Outcomes in Cats With Invasive Mammary Carcinoma, Spontaneous Immunocompetent Animal Models of Breast Cancer. J Comp Pathol 2020. [DOI: 10.1016/j.jcpa.2019.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2019; 30:1842. [PMID: 31407010 PMCID: PMC6927326 DOI: 10.1093/annonc/mdz215] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Mosele F, Lusque A, Tran Dien A, Droin N, Le Tourneau C, Sablin M, Lacroix L, Miran I, Jovelet C, Bieche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Martin M, Campone M, Bondarenko I, Sakaeva D, Krishnamurthy S, Roman L, Lebedeva L, Vedovato JC, Aapro M. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Ann Oncol 2019; 29:1195-1202. [PMID: 29447329 DOI: 10.1093/annonc/mdy063] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Background Capecitabine is an approved standard therapy for anthracycline- and taxane-pretreated locally advanced or metastatic breast cancer (BC). Vinflunine has demonstrated single-agent activity in phase II studies in this setting and activity and tolerability when combined with capecitabine. We compared the combination of vinflunine plus capecitabine (VC) with single-agent capecitabine. Patients and methods Patients with locally recurrent/metastatic BC previously treated or resistant to an anthracycline and resistant to taxane therapy were randomly assigned to either vinflunine (280 mg/m2, day 1) plus oral capecitabine [825 mg/m2 twice daily (b.i.d.), days 1-14] every 3 weeks (q3w) or single-agent oral capecitabine (1250 mg/m2 b.i.d., days 1-14) q3w. The primary end point was progression-free survival (PFS) assessed by an independent review committee. The study had 90% power to detect a 30% improvement in PFS. Results Overall, 770 patients were randomised. PFS was significantly longer with VC than with capecitabine alone [hazard ratio, 0.84, 95% confidence interval (CI), 0.71-0.99; log-rank P = 0.043; median 5.6 versus 4.3 months, respectively]. Median overall survival was 13.9 versus 11.7 months with VC versus capecitabine alone, respectively (hazard ratio, 0.98; 95% CI, 0.83-1.15; log-rank P = 0.77). No difference in quality of life was observed between the two treatment arms. The most common adverse events (NCI CTCAE version 3.0) in the combination arm were haematological and gastrointestinal. Grade 4 neutropenia was more frequent with VC (12% versus 1% with capecitabine alone); febrile neutropenia occurred in 2% versus 0.5%, respectively. Hand-foot syndrome was less frequent with VC (grade 3: 4% versus 19% for capecitabine alone). Peripheral neuropathy was uncommon in both arms (grade 3: 1% versus 0.3%). Conclusions Vinflunine combined with capecitabine demonstrated a modest improvement in PFS and an acceptable safety profile compared with capecitabine alone in patients with anthracycline- and taxane-pretreated locally recurrent/metastatic BC. ClinicalTrials.gov NCT01095003.
Collapse
Affiliation(s)
- M Martin
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - M Campone
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - I Bondarenko
- Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, City Multidisciplinary Clinical Hospital No. 4, Dnipropetrovsk, Ukraine
| | - D Sakaeva
- State Budgetary Healthcare Institution, Republican Clinical Oncology Dispensary of MoH of Bashkortostan Republic, Ufa, Russia
| | - S Krishnamurthy
- Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
| | - L Roman
- Leningrad Regional Oncology Dispensary, St Petersburg
| | - L Lebedeva
- Department of Chemotherapy, Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russia
| | - J-C Vedovato
- Clinical Development Oncology, Oncology Innovation Unit, Institut de Recherche Pierre Fabre, Toulouse, France
| | - M Aapro
- Cancer Center, Clinique de Genolier, Genolier, Switzerland
| |
Collapse
|
31
|
Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Gonçalves A, Uwer L, Eymard JC, Petit T, Mouret-Reynier MA, Chamorey E, Simon G, Saghatchian M, Cailliot C, Le Tourneau C. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. Breast 2019; 49:17-24. [PMID: 31675683 PMCID: PMC7375625 DOI: 10.1016/j.breast.2019.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 10/09/2019] [Accepted: 10/11/2019] [Indexed: 12/25/2022] Open
Abstract
Purpose The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such as expression of estrogen receptor are known predictive factors of TFMR. The CinéBreast study aimed to identify predictive factors of the time to TFMR. Methods The French Epidemiological Strategy and Medical Economics (ESME) Metastatic Breast Cancer (MBC) Database (NCT03275311) was used, which contains data from a cohort of metastatic breast cancer patients from 2008 to 2016 using retrospective data collection. It is a national multi-centre database. The impact of TFMR on overall survival (OS) since first metastasis was also evaluated. Results Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence. Median follow up was 56 months. Median TFMR was 59 months (<24: 20%, 24–60: 31%, 60–120: 25%, >120: 24%). HER2+ and TNBC were respectively 4 times and 12 times (p < 0.0001) more likely to have a recurrence within 2 years when compared to the luminal subgroup. Short TFMR and HR-/HER2-subtype significantly correlated with a poor OS in multivariate analysis. Some patients with MBC (20% in HER2+, 10% in ER+/HER2-and <5% in the ER-/HER2-) were long-term survivors in all 3 subgroups. Conclusions In this large-scale real-life data study, patients with a TNBC metastatic recurrence had a shorter TFMR. Short TFMR significantly correlated with worse overall survival. ESME is a large-scale real-life database of 16 702 metastatic breast cancer patients. A short time to first metastatic recurrence is associated with poor overall survival. Triple-negative tumours were more likely to recur early than HR+ and HER2+ tumours.
Collapse
Affiliation(s)
- P Gougis
- Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; Department of Clinical Pharmacology, Centre D'Investigation Clinique Paris-Est, AP-HP, Pitié-Salpêtrière Hospital, PSL University, CLIP² Galilée, Paris, France
| | - M Carton
- Department of Biostatistics, Institut Curie, Saint-Cloud, France
| | - C Tchokothe
- Department of Biostatistics, Institut Curie, Saint-Cloud, France
| | - M Campone
- Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Nantes and Angers, France
| | - F Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
| | - A Mailliez
- Department of Breast Cancer, Centre Oscar Lambret, Lille, France
| | - C Levy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - W Jacot
- Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier, France
| | - M Debled
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France
| | - M Leheurteur
- Department of Medical Oncology, Henri Becquerel Centre, Rouen, France
| | - T Bachelot
- Department of Biostatistics, Centre Léon Bérard, Lyon, France
| | - A Hennequin
- Department of Medical Oncology, Center Georges François Leclerc, Dijon, France
| | - C Perrin
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
| | - A Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - L Uwer
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
| | - J C Eymard
- Department of Medical Oncology, Centre Jean Godinot, Reims, France
| | - T Petit
- Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France
| | - M A Mouret-Reynier
- Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France
| | - E Chamorey
- Department of Biostatistics, Centre Antoine Lacassagne, Nice, France
| | - G Simon
- Department of Research and Development, R&D Unicancer, Paris, France
| | - M Saghatchian
- Department of Biostatistics, Institut Curie, Saint-Cloud, France
| | - C Cailliot
- Department of Research and Development, R&D Unicancer, Paris, France
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; U900 INSERM Research Unit, Saint-Cloud, France.
| |
Collapse
|
32
|
De Laurentiis M, Ring A, Campone M, Bachelot T, Jacot W, Marchetti P, Timcheva C, De Valk B, Gombos A, Menon-Singh L, Wu J, Zhou K, Neven P. Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Rugo H, André F, Yamashita T, Cerda H, Toledano I, Stemmer S, Cruz Jurado J, Juric D, Mayer I, Ciruelos E, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lorenzo I, Miller M, Loibl S. Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palácová M, Chatterjee S, Menon-Singh L, Wu J, Zhou K, Martin M. Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Howell S, Campone M, Cortés J, Duhoux F, Ross S, Morris T, Franklin S. Final results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.036] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Campone M, Rugo H, Rubovszky G, André F, Loibl S, Iwata H, Conte P, Mayer I, Juric D, Yamashita T, Lorenzo I, Ridolfi A, Ciruelos E. Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
D’Hondt V, Canon JL, ROCA L, Levy C, Pierga JY, Du FL, Campone M, Desmoulins I, Viens P, Debled M, Ferrero JM, Serin D, Bessard ACH, Brain E, Dohollou N, Orfeuvre H, Lemonnier J, Roche H, Delaloge S, Dalenc F. Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Diéras V, Han H, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla S, Bondarenko I, Campone M, Jakobsen E, Jalving M, Oprean C, Palácová M, Park Y, Shparyk Y, Yañez E, Dudley M, Ratajczak C, Maag D, Arun B. Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.008] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
39
|
Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol 2019; 30:1381-1392. [PMID: 31114846 PMCID: PMC8887589 DOI: 10.1093/annonc/mdz163] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023] Open
Abstract
BACKGROUND Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of emactuzumab, as monotherapy and in combination with paclitaxel, in patients with advanced solid tumors. PATIENTS AND METHODS This open-label, phase Ia/b study comprised two parts (dose escalation and dose expansion), each containing two arms (emactuzumab, every 2 or 3 weeks, as monotherapy or in combination with paclitaxel 80 mg/m2 weekly). The dose-escalation part explored the maximum tolerated dose and optimal biological dose (OBD). The dose-expansion part extended the safety assessment and investigated the objective response rate. A PK/PD analysis of serial blood, skin and tumor biopsies was used to explore proof of mechanism and confirm the OBD. RESULTS No maximum tolerated dose was reached in either study arm, and the safety profile of emactuzumab alone and in combination does not appear to preclude its use. No patients receiving emactuzumab monotherapy showed an objective response; the objective response rate for emactuzumab in combination with paclitaxel was 7% across all doses. Skin macrophages rather than peripheral blood monocytes or circulating colony-stimulating factor-1 were identified as an optimal surrogate PD marker to select the OBD. Emactuzumab treatment alone and in combination with paclitaxel resulted in a plateau of immunosuppressive TAM reduction at the OBD of 1000 mg administered every 2 weeks. CONCLUSIONS Emactuzumab showed specific reduction of immunosuppressive TAMs at the OBD in both treatment arms but did not result in clinically relevant antitumor activity alone or in combination with paclitaxel. (ClinicalTrials.gov Identifier: NCT01494688).
Collapse
Affiliation(s)
- C A Gomez-Roca
- Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
| | - A Italiano
- Department of Medical Oncology, Institut Bergonié, Bordeaux.
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud; INSERM U900 Research Unit, Saint-Cloud; Paris-Saclay University, Paris
| | - P A Cassier
- Department of Medicine, Centre Léon Bérard, Lyon, France
| | - M Toulmonde
- Department of Medical Oncology, Institut Bergonié, Bordeaux
| | - S P D'Angelo
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA
| | - M Campone
- ICO René Gauducheau, Saint-Herblain, France
| | - K L Weber
- Department of Orthopedic Oncology, Penn Medicine, Pennsylvania, USA
| | - D Loirat
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud
| | - M A Cannarile
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - A-M Jegg
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - C Ries
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - R Christen
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - G Meneses-Lorente
- Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn Garden City
| | - W Jacob
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - I Klaman
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - C-H Ooi
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - C Watson
- A4P Consulting Ltd, Sandwich, UK
| | - K Wonde
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - B Reis
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - F Michielin
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - D Rüttinger
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - J-P Delord
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud
| | - J-Y Blay
- Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse
| |
Collapse
|
40
|
Loibl S, Conte P, Campone M, Mayer I, Lu YS, Denduluri N, Wilke C, Ridolfi A, André F. Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz100.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Bordes V, Palpacuer C, FRICK C, Leperlier F, Dezellus A, De Blay P, Delay F, Sauterey B, Augereau P, Duros S, Lefeuvre-Plesse C, Lavau S, Durand LM, Mouret MA, Gremeau AS, Campone M, Mirallie S. Abstract P4-16-02: Fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Final results of PRESAGE trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-16-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the most frequent form of cancer in young women. For these patients, breast cancer is generally more aggressive and chemotherapy is more often needed. Chemotherapy is commonly associated with amenorrhea and a decrease of ovarian reserve depending on the patient's age, agents and dose. Embryo, oocyte and ovarian tissue cryopreservation are the three options to preserve fertility. Embryo and oocyte cryopreservation require controlled ovarian stimulation (COS). The use of COS is associated with an increase of estradiol levels. It led to develop protocols using Tamoxifen or Letrozole combined with FSH to protect patients of the potential deleterious effects of the COS. PRESAGE is the first French prospective multicenter feasibility study about fertility preservation by COS combined with Tamoxifen and oocyte +/- embryo cryopreservation before neoadjuvant (NAC) or adjuvant (AC) chemotherapy for breast cancer.
Material and method: Prospective multicenter study for patients of less than 40 years, with a breast cancer, for whom a treatment of NAC or AC is indicated and who wish to preserve their fertility. The main objective was to evaluate the feasibility of a COS associating Tamoxifen with FSH followed by an oocyte+/- embryo cryopreservation. The secondary objectives were to evaluate the average deadline prior to the beginning of the chemotherapy and the impact of the type of COS (depending on the phase of the menstrual cycle, conventional-start or random-start COS protocol) on the number and the quality of oocytes harvested. Statistical analysis was performed using SAS statistical software version 9.4 (SAS Institute, Cary, NC).
Results: 101 patients were included between February 2014 and July 2017 and 97 patients were eligible for statistical analysis. Mean age of the patients was 31,5 +/- 4 years, the half of them was nulliparous (53/97) and 23,7 % (23/97) were single. They presented mainly SBR II or III (91/96, 94,8 %) lesions, ER + (66/96, 68,7 %). 38 patients benefited from a NAC and 59 of an AC.
We have found a significant shorter care (time between the first oncologist's consultation and the beginning of the chemotherapy) according to the type of chemotherapy: 29,7 +/- 15,6 days in NAC group vs 45,2 +/- 21,5 days in AC group (p=0,003) with the same duration of ovarian stimulation in the two groups (10,5 +/-2 days).
The success rate of the COS procedure was 90,7 % (88/97) with no significant difference between the groups according to the type of COS (p = 0.06) or the type of chemotherapy (AC vs. NAC p= 0,3). In the 88 patients who had oocyte retrieval, the number of oocytes harvested per patient was 12,8 +/- 7,8 , the number of oocytes preserved was 9,7 +/- 6,1 and an IVF was performed in 12,5% of patients (11/88) with 5,1 +/- 3,1 embryos obtained. We have found no impact of the type of chemotherapy or the type of COS on the number of oocytes or embryos preserved.
Conclusion: with a high success rate (90,7%), our study suggests that COS with Tamoxifen and FSH is feasible before adjuvant or neoadjuvant chemotherapy in breast cancer patients. We also show that COS procedure before neoadjuvant chemotherapy can be realized without increasing the time before introducing chemotherapy.
Citation Format: Bordes V, Palpacuer C, FRICK C, Leperlier F, Dezellus A, De Blay P, Delay F, Sauterey B, Augereau P, Duros S, Lefeuvre-Plesse C, Lavau S, Durand LM, Mouret MA, Gremeau AS, Campone M, Mirallie S. Fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Final results of PRESAGE trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-16-02.
Collapse
Affiliation(s)
- V Bordes
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - C Palpacuer
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - C FRICK
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - F Leperlier
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - A Dezellus
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - P De Blay
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - F Delay
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - B Sauterey
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - P Augereau
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - S Duros
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - C Lefeuvre-Plesse
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - S Lavau
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - LM Durand
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - MA Mouret
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - AS Gremeau
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - M Campone
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| | - S Mirallie
- ICO Rene Gauducheau, Nantes, France; CHU, Nantes, France; CHD, La Roche sur Yon, France; ICO Paul Papin, Angers, France; CHU, Rennes, France; Centre Eugene Marquis, Rennes, France; CHU, Limoges, France; Centre Jean Perrin, Clermont Ferrand, France; CHU, Clermont Ferrand, France
| |
Collapse
|
42
|
Monneur A, Bertucci F, Lardy-Cleaud A, Augereau P, Debled M, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Bachelot T, Ferrero JM, Guiu S, Uwer L, Campone M, Cottu P, Jouannaud C, De la Motte Rouge T, Leheurteur M, Petit T, Pistilli B, Dalenc F, Simon G, Robain M, Viens P, Lerebours F, Gonçalves A. Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-17-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Primary inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Survival of IBC patients has been improved by multimodal therapy. However 5-year overall survival (OS) still remains close to 50-60%, due to high risk of disseminated disease. Given the low incidence, prognosis of metastatic cases stages is poorly described.
Methods:This study aimed to describe OS of IBC (T4d AJCC TNM classification) with upfront or recurrent metastatic disease compared with non-IBC patients in the ESME database (N=16,702 patients). OS was calculated from the diagnosis of metastasis to the date of death (from any cause), or censored to date of latest news. Secondary objectives included progression-free survival (PFS).
Results:From 2008 to 2014, 7,465 patients with diagnosis of MBC and known clinical status of their primary tumor (T) were identified, including 582 IBC (T4d) and 6,883 non-IBC. As expected, metastatic IBC was associated with pejorative features compared to non-IBC, with less hormonal receptors-positive tumors (44% vs 65.6%), more HER2-positive (30% vs 18.6%) or triple-negative (25.9% vs 15.8%) cases (p<0.001), more frequent upfront M1 stage (53.3% vs 27.7%; p<0.001), and shorter median disease-free interval (2.02 years vs. 4.9 years; p<0.001). With a median follow-up of 50.2 months (0-104), median OS was 28.4 [95%CI 24-33.8] versus 37.2 months [95%CI 36.1-38.5] in metastatic IBC and non-IBC cases respectively (p<0.0001, log-rank test). By multivariate Cox model with adjustment for major prognostic factors [including age, disease-free interval, type of relapse, visceral metastases, molecular subtype, grade], OS was significantly shorter in the metastatic IBC group compared with non-IBC group (HR 1.25 [95%CI 1.1-1.4], p=0.0002). Of note, survival of metastatic IBC patients improved over the last years: median OS 24 months [95%CI 20-31.9], 29 months [95%CI 21.7-39.9] and 36 months [95%CI 27.9-NE] if diagnosed before 2011, between 2011 and 2012, or after 2012 respectively (p=0.003). Such improvement was not observed in non-IBC patients. IBC was associated with shorter median PFS under first line systemic treatment compared with non-IBC (7.2 months [95%CI 6.6-8.3] vs 9.5 months [95%CI 9.1-9.8] respectively, p=0.0136). This was maintained in a multivariate Cox model adjusting for same factors as for OS (HR 1.15 [95%CI 1-1.3], p=0.0050).
Compared with non-IBC, synchronous metastatic IBC showed worse median OS and PFS (39.9 months [95%CI 34.2-45.3] vs 48.4 months [95%CI 46.3-50.8], p=0.0035; 10 months [95%CI 8.8-12.7] vs 14.5 months [95%CI 13.6-15.7], p=0.0027, respectively. Similar results were obtained in metachronous metastatic cases (20.01 months [95%CI 17.1-21.2] vs 32.8 months [95%CI 31.5-34.3], p<0.0001; 5.1 months [95%CI 4.1-6] vs 7.9 months [95%CI 7.6-8.3], p<0.0001, respectively).
Conclusion:In this large national and multicentric study, IBC is a major and independent factor associated with adverse outcome in metastatic setting. Of note, the independent adverse impact on PFS identified in this study may suggest a lower sensitivity of metastatic IBC to available therapeutics. However, results seem to improve in the last years. Detailed analysis according to phenotype will be available.
Citation Format: Monneur A, Bertucci F, Lardy-Cleaud A, Augereau P, Debled M, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Bachelot T, Ferrero J-M, Guiu S, Uwer L, Campone M, Cottu P, Jouannaud C, De la Motte Rouge T, Leheurteur M, Petit T, Pistilli B, Dalenc F, Simon G, Robain M, Viens P, Lerebours F, Gonçalves A. Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-17-04.
Collapse
Affiliation(s)
- A Monneur
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Bertucci
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Lardy-Cleaud
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Augereau
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Debled
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - C Levy
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - MA Mouret-Reynier
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - B Coudert
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Mailliez
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T Bachelot
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - J-M Ferrero
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - S Guiu
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - L Uwer
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Campone
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Cottu
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - C Jouannaud
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T De la Motte Rouge
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Leheurteur
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T Petit
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - B Pistilli
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Dalenc
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - G Simon
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Robain
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Viens
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Lerebours
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Gonçalves
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| |
Collapse
|
43
|
Burris HA, Chan A, Im SA, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the safety of RIB-based regimens of interest for the proposed indication (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) using pooled data from three Phase III trials (MONALEESA [ML]-2 [NCT01958021], -3 [NCT02422615], and -7 [NCT02278120]).
Methods: Postmenopausal pts with HR+, HER2– ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + letrozole (LET; 2.5 mg/day; ML-2 [no prior ET for ABC]) or FUL (500 mg, Days 1 and 15 of Cycle 1, then Day 1 of every cycle thereafter; ML-3; no or ≤1 prior line of ET for ABC]). Premenopausal pts (ML-7; no prior ET and ≤1 chemotherapy for ABC]) received RIB or PBO + anastrozole (1 mg/day)/LET (2.5 mg/day) + goserelin (3.6 mg every 28 days). Adverse events (AEs) were characterized per Common Terminology Criteria for Adverse Events v4.03; safety analyses included time to first event, duration of event, and rate of associated RIB/PBO discontinuations.
Results: Data for 1883 pts were pooled; 1065 pts received RIB + ET and 818 pts received PBO + ET (median exposure to study treatment: 17 and 13 months, respectively). Exposure-adjusted incidence rates for AEs of special interest were 561 and 131 per 100 pt-years in the RIB and PBO arms, respectively. The most common all-causality Grade 3/4 AEs (≥10% in any arm; RIB vs PBO) were neutropenia (59% vs 2%), leukopenia (18% vs 1%), and hypertension (13% vs 13%). A new Fridericia's corrected QT interval (QTcF) >480 ms occurred in (n/N) 52/1054 (5%) vs 11/814 (1%) pts in the RIB vs PBO arms; a new QTcF >500 ms occurred in 14/1054 (1%) vs 1/814 (<1%) pts. Median time to first event for Grade ≥2 neutropenia, elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and QTc prolongation in the RIB arm was 2, 12, and 2 weeks, respectively; median duration of first Grade ≥2 event was 4, 4, and 2 weeks. In the RIB arm vs PBO arms, 7% vs 3% of pts discontinued study treatment due to AEs; common all-grade AEs leading to RIB/PBO discontinuation (≥2% in any arm) were elevated ALT (4% vs <1%) and elevated AST (2% vs 1%). Discontinuation due to QT prolongation occurred in 4 pts in the RIB arm and 2 in the PBO arm (both <1%). All-grade serious AEs occurred in 25% of pts in the RIB arm vs 15% of pts in the PBO arm.
Conclusions: RIB in combination with various ET partners continues to demonstrate a predictable and manageable tolerability profile across a broad population of pts with HR+, HER2– ABC.
Citation Format: Burris HA, Chan A, Im S-A, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-15.
Collapse
Affiliation(s)
- HA Burris
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Chan
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S-A Im
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S Chia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - D Tripathy
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - FJ Esteva
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - M Campone
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Bardia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - O Kong
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - W Bao
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - I Diaz-Padilla
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - K Rodriguez Lorenc
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - DA Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| |
Collapse
|
44
|
Campone M, Guette C, Lasla H, Gouraud W, Guérin-Charbonnel C, Jézéquel P. Abstract P3-07-10: Triple negative breast cancer tumors subtyping by means of integrated transcriptome and proteome analyses. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-07-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC) and therefore, molecular subtyping and identification of therapeutic pathways are required to optimize medical care. The aim of the present work was to confirm unsupervised analysis of TNBC transcriptomic data by means of proteomics.
Methods: Transcriptome and proteome of 83 TNBC macrodissected tumors were screened in parallel. These patients were described in a previous study [Jézéquel, et al., Breast Cancer research (2015) 17, 43). Transcriptome screening was performed using Affymetrix Human Genome U133 Plus 2.0 Arrays (AffymetrixÒ, Santa Clara, CA). Proteome profiling was performed by means of iTRAQ-OFFGEL-LC-MS/MS approach [Campone, et al, Mol Cell Proteomics (2015) 14, 2936-2946].
Results: Unsupervised analysis of transcriptomic data identified three molecular clusters within TNBC: one molecular apocrine (C1: 20%) and two basal-like-enriched (C2: 47% and C3: 33%). C2 presented pro-tumorigenic immune response and C3 exhibited adaptive immune response.
iTRAQ-OFFGEL-LC-MS/MS screening identified 366 out of 1,929 unique proteins, which were quantified in at least 70% of TNBC tumors and therefore could be used for analysis. Principal component analysis (PCA) with projection of 83 TNBC onto the first principal plane showed inhomogeneous distribution: one largest group (n = 77) and two outlier groups composed of three tumors, which have been eliminated for the rest of the work. In order to look for the existence of a partition of 77 TNBC cohort based on proteomics data, we performed clustering analysis using fuzzy clustering. Gap statistic was used to estimate the optimal number of clusters. This number was equal to one, whatever the metric. PCA and estimation of the number of clusters results lead us to conclude that iTRAQ-OFFGEL-LC-MS/MS data could not be used alone to subtype our 77 TNBC cohort most probably due to insufficient information content of proteomics matrix.
TNBC cluster assignment, based on transcriptomics was applied to these tumors. Sixty-two out 366 ANOVA analyses were significant between the three clusters (p < 0.05). Twenty-two differentially expressed proteins between C1, C2 and C3 belonged to biological categories, which characterized these TNBC clusters. Gene Ontology enrichment analysis based on the set of proteins highly expressed in C2 compared to C1 and C3 (n = 21) displayed enrichment in genes coding for protein involved in extracellular matrix, wound response and RNA splicing.
Table 1.Proteins found differentially expressed between TNBC cluster defined by means of transcriptomicsProteinsBiological categoriesClustersK2C7, K2C8, K1C18, K1C19LuminalC1FAS, UGDHAndrogen induced (molecular apocrine) LDHBBasal-likeC2PLMN, POSTN, FLNB, TENA, PLOD3, FSCN1, SERPH, FINCInvasion, extracellular matrix MOESBasal-likeC3STAT1, SYWC, AMPL, SAMH1Interferon pathway IGKC, IGHMImmunoglobulines
Conclusion: Although iTRAQ-OFFGEL-LC-MS/MS screening did not contain enough information for cluster identification, 22 proteins, which were differentially expressed between the three clusters corroborate transcriptomic subtyping of TNBC.
Citation Format: Campone M, Guette C, Lasla H, Gouraud W, Guérin-Charbonnel C, Jézéquel P. Triple negative breast cancer tumors subtyping by means of integrated transcriptome and proteome analyses [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-10.
Collapse
Affiliation(s)
- M Campone
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| | - C Guette
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| | - H Lasla
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| | - W Gouraud
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| | - C Guérin-Charbonnel
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| | - P Jézéquel
- Oncologie Médicale, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut de Cancérologie de l'Ouest - Paul Papin, INSERM U892, CNRS 6299, Angers, France; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Unité Mixte de Génomique du Cancer, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; INSERM U1232, IRS-UN, Nantes, France
| |
Collapse
|
45
|
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. Cancer Chemother Pharmacol 2019; 83:743-753. [DOI: 10.1007/s00280-018-03765-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 12/27/2018] [Indexed: 11/25/2022]
|
46
|
Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene 2019; 38:3261-3273. [PMID: 30631150 PMCID: PMC6756023 DOI: 10.1038/s41388-018-0635-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 11/22/2018] [Accepted: 11/23/2018] [Indexed: 12/24/2022]
Abstract
Selective inhibition of BCL-2 is expected to enhance therapeutic vulnerability in luminal estrogen receptor-positive breast cancers. We show here that the BCL-2 dependency of luminal tumor cells is nevertheless mitigated by breast cancer-associated fibroblasts (bCAFs) in a manner that defines MCL-1 as another critical therapeutic target. bCAFs favor MCL-1 expression and apoptotic resistance in luminal cancer cells in a IL-6 dependent manner while their own, robust, survival also relies on MCL-1. Studies based on ex vivo cultures of human luminal breast cancer tissues further argue that the contribution of stroma-derived signals to MCL-1 expression shapes BCL-2 dependency. Thus, MCL-1 inhibitors are beneficial for targeted apoptosis of breast tumor ecosystems, even in a subtype where MCL-1 dependency is not intrinsically driven by oncogenic pathways.
Collapse
Affiliation(s)
- K Louault
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - T L Bonneaud
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - C Séveno
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - P Gomez-Bougie
- SIRIC ILIAD, Angers, Nantes, France.,CRCINA, Team 10, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - F Nguyen
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,ONIRIS, Nantes Atlantic College of Veterinary Medicine Food Science and Engineering, Animal Cancers, Nantes, France
| | - F Gautier
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - N Bourgeois
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - D Loussouarn
- Service d'Anatomie Pathologique, CHU Nantes, Nantes, France
| | - O Kerdraon
- SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - S Barillé-Nion
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - P Jézéquel
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - M Campone
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - M Amiot
- SIRIC ILIAD, Angers, Nantes, France.,CRCINA, Team 10, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - P P Juin
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,SIRIC ILIAD, Angers, Nantes, France. .,ICO René Gauducheau, Saint Herblain, France. .,CNRS GDR3697 Micronit, Tours, France.
| | - F Souazé
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,SIRIC ILIAD, Angers, Nantes, France. .,CNRS GDR3697 Micronit, Tours, France.
| |
Collapse
|
47
|
Dagher E, Truchot Y, Gawronski L, Loussouarn D, Abadie J, Fanuel D, Campone M, Nguyen F. Expression and prognostic value of the breast cancer stem-cell markers ALDH1A1 and Sox2 in feline invasive mammary carcinomas. J Comp Pathol 2019. [DOI: 10.1016/j.jcpa.2018.10.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Quereux G, Souchard M, Bourdon M, Campone M, Dravet F, Bonnaud A. Étude du parcours de vie après un cancer grâce à l’analyse lexicale. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Zamagni C, Campone M, Kudryavcev I, Brown-Glaberman U, Cottu P, Ring A, Lu J, Martín M, De Laurentiis M, Zhou K, Wu J, Menon L, Azim H. Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H, Iwata H, Conte P, Mayer I, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.010] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|